Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their ...

Dr. Daniel Olson is hoping it's the first step in a whole new way of treating cancers like the one that was threatening Alla ...

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

It is the first comprehensive cellular analysis of ALS, carried out using single-cell RNA sequencing in 14 patients and 14 ...

All nine patients showed a “successful anti-cancer immune response” after getting the vaccine. After an average of 34.7 months, they all remained cancer-free.

Researchers determine a complex immune infiltrate pattern based on a newly constructed immune map developed using pancreatic ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with ...

The immune system plays a key role in detecting and destroying cancer cells. Cancer immunotherapy works by programming immune cells to recognize and eliminate cancer cells.